Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 10/20 | 0.41 |
| ▸ | BRAF | P15056 | 7/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22797751 | 0.88 | MEN1 (0.48) | KDRBRAFMEN1LMNAPOLB | |
| SCHEMBL20595168 | 0.85 | KDR (0.46) | GSK3BKDRBRAFGSK3ATYK2 | |
| SCHEMBL22798424 | 0.84 | GSK3B (0.53) | GSK3BKDRBRAFGSK3ATYK2 | |
| SCHEMBL2716568 | 0.82 | SCN3A (0.51) | KDRBRAFMALT1MEN1LMNA | |
| SCHEMBL20595232 | 0.81 | SCN9A (0.48) | GSK3BKDRBRAFGSK3AMEN1 | |
| SCHEMBL22798296 | 0.80 | KDR (0.45) | KDRBRAFMEN1LMNAPOLB | |
| SCHEMBL20595235 | 0.80 | KDR (0.44) | KDRBRAFMEN1LMNAPOLB | |
| SCHEMBL2715423 | 0.79 | KDR (0.47) | GSK3BKDRBRAFJAK1GSK3A | |
| SCHEMBL22797760 | 0.79 | SCN9A (0.54) | GSK3BKDRBRAFGSK3AMEN1 | |
| SCHEMBL20595227 | 0.79 | KMT2A (0.41) | GSK3BKDRBRAFMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | claimed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | claimed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | claimed |
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | GSK3B 1727/4885KDR 4122/4885BRAF 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.